Intestinal permeation enhancers for oral peptide delivery

Sam Maher, Randall Mrsny, David J. Brayden

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Intestinal permeation enhancers (PEs) are one of the most widely tested strategies to improve oral delivery of therapeutic peptides. This article assesses the intestinal permeation enhancement action of over 250 PEs that have been tested in intestinal delivery models. In depth analysis of pre-clinical data is presented for PEs as components of proprietary delivery systems that have progressed to clinical trials. Given the importance of co-presentation of sufficiently high concentrations of PE and peptide at the small intestinal epithelium, there is an emphasis on studies where PEs have been formulated with poorly permeable molecules in solid dosage forms and lipoidal dispersions.
Original languageEnglish
Pages (from-to)277-319
JournalAdvanced Drug Delivery Reviews
Volume106
Issue numberPart B
DOIs
Publication statusPublished - 15 Nov 2016

Fingerprint

Peptides
Dosage Forms
Intestinal Mucosa
Clinical Trials
Therapeutics

Cite this

Intestinal permeation enhancers for oral peptide delivery. / Maher, Sam; Mrsny, Randall; Brayden, David J.

In: Advanced Drug Delivery Reviews, Vol. 106, No. Part B, 15.11.2016, p. 277-319.

Research output: Contribution to journalArticle

Maher, Sam ; Mrsny, Randall ; Brayden, David J. / Intestinal permeation enhancers for oral peptide delivery. In: Advanced Drug Delivery Reviews. 2016 ; Vol. 106, No. Part B. pp. 277-319.
@article{96f20102a303431585cffc50d273ae43,
title = "Intestinal permeation enhancers for oral peptide delivery",
abstract = "Intestinal permeation enhancers (PEs) are one of the most widely tested strategies to improve oral delivery of therapeutic peptides. This article assesses the intestinal permeation enhancement action of over 250 PEs that have been tested in intestinal delivery models. In depth analysis of pre-clinical data is presented for PEs as components of proprietary delivery systems that have progressed to clinical trials. Given the importance of co-presentation of sufficiently high concentrations of PE and peptide at the small intestinal epithelium, there is an emphasis on studies where PEs have been formulated with poorly permeable molecules in solid dosage forms and lipoidal dispersions.",
author = "Sam Maher and Randall Mrsny and Brayden, {David J.}",
year = "2016",
month = "11",
day = "15",
doi = "10.1016/j.addr.2016.06.005",
language = "English",
volume = "106",
pages = "277--319",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",
number = "Part B",

}

TY - JOUR

T1 - Intestinal permeation enhancers for oral peptide delivery

AU - Maher, Sam

AU - Mrsny, Randall

AU - Brayden, David J.

PY - 2016/11/15

Y1 - 2016/11/15

N2 - Intestinal permeation enhancers (PEs) are one of the most widely tested strategies to improve oral delivery of therapeutic peptides. This article assesses the intestinal permeation enhancement action of over 250 PEs that have been tested in intestinal delivery models. In depth analysis of pre-clinical data is presented for PEs as components of proprietary delivery systems that have progressed to clinical trials. Given the importance of co-presentation of sufficiently high concentrations of PE and peptide at the small intestinal epithelium, there is an emphasis on studies where PEs have been formulated with poorly permeable molecules in solid dosage forms and lipoidal dispersions.

AB - Intestinal permeation enhancers (PEs) are one of the most widely tested strategies to improve oral delivery of therapeutic peptides. This article assesses the intestinal permeation enhancement action of over 250 PEs that have been tested in intestinal delivery models. In depth analysis of pre-clinical data is presented for PEs as components of proprietary delivery systems that have progressed to clinical trials. Given the importance of co-presentation of sufficiently high concentrations of PE and peptide at the small intestinal epithelium, there is an emphasis on studies where PEs have been formulated with poorly permeable molecules in solid dosage forms and lipoidal dispersions.

UR - http://dx.doi.org/10.1016/j.addr.2016.06.005

U2 - 10.1016/j.addr.2016.06.005

DO - 10.1016/j.addr.2016.06.005

M3 - Article

VL - 106

SP - 277

EP - 319

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

IS - Part B

ER -